Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints
Viridian Therapeutics will be reporting data from a second Phase III trial of veligrotug before the end of 2024.
Viridian Therapeutics will be reporting data from a second Phase III trial of veligrotug before the end of 2024.
Results from AstraZeneca’s completed clinical studies will be shared with regulatory authorities by the end of this year.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
As mpox spreads, ‘national governments have a moral responsibility to help’
Ultromics’s EchoGo misses primary endpoint in heart disease trial
NHS report touts effectiveness of Skin Analytics’ DERM AI melanoma tool
Spectral AI hits enrollment goal at burn centres for AI-powered assessment tech